Abstract:Background Over the past decade, a new class of drugs called CFTR (cystic fibrosis transmembrane conductance regulator) modulators have shown to be able to improve clinical outcomes in patient with Cystic Fibrosis. In this analysis, we have extensively reviewed the regulatory pathways and decisions adopted by FDA and EMA to speed up the development, the review and the approval of these drugs, with the aim of identifying possible clinical and public health implications associated with differences. Results CFTR modulators have been developed towards addressing three main genetic domains: (1) F508del homozygous (F508del/F508del), (2) F508del heterozygous, and (3) genotypes not carrying F508del mutation; and expanded from adult to paediatric population. Programs to expedite the reviewing and licensing of CFTR modulators were extensively adopted by FDA and EMA. All CFTR modulators have been licensed in the US as orphan drugs, but in the EU the orphan status for LUM/IVA was not confirmed at the time of marketing authorization as results from the pivotal trial were not considered clinically significant. While FDA and EMA approved CFTR modulators on the basis of results from phase III double-blind RCTs, main differences were found on the extension of indications: FDA accepted non-clinical evidence considering a recovery of the CFTR function ≥ 10% based on chloride transport, a reliable indicator to correlate with improvement in clinical outcomes. By contrast, EMA did not deem preclinical data sufficient to expand the label of CFTR modulators without confirmatory clinical data. Conclusions Regulators played an important role in fostering the development and approval of CFTR modulators. However, differences were found between FDA and EMA in the way of reviewing and licensing CFTR modulators, which extended beyond semantics affecting patients' eligibility and access: FDA's approach was more mechanistic/biology-driven while the EMA's one was more oriented by clinical evidence. This might refer to the connection between the EMA and the Member States, which tends to base decisions on pricing and reimbursement on clinical data rather than pre-clinical ones. Here we have proposed a two-step personalized-based model to merge the ethical commitment of ensuring larger access to all potential eligible patients (including those harboring very rare mutations) with the one of ensuring access to clinically assessed and effective medicines through Real World Data.

Cystic fibrosis patients of minority race and ethnicity less likely eligible for CFTR modulators based on CFTR genotype

Disparities in outcomes by race and ethnicity in the Canadian cystic fibrosis population

A survey: Understanding the health and perspectives of people with CF not benefiting from CFTR modulators

Expanding the Impact of New Cystic Fibrosis Therapies in Low‐ and Middle‐Income Countries

Comparison of clinical features of cystic fibrosis patients eligible but not on CFTR modulators to ineligible for CFTR modulators

Phenotypic Evaluation of Rare Cystic Fibrosis Transmembrane Conductance Regulator Mutation Combinations in People with Cystic Fibrosis in Queensland, Australia

In vitro modulator responsiveness of 655 CFTR variants found in people with cystic fibrosis

Functional Consequences of CFTR Interactions in Cystic Fibrosis

Comparison of Reporting Quality in National Cystic Fibrosis Patient Registries: Implications for Identifying Use of Novel CFTR Modulators

xTrends in racial and ethnic disparities in pediatric lung transplantation in the United States

A bibliometric analysis of cystic fibrosis transmembrane conductance regulators

The impact of switching to race-neutral reference equations on FEV 1 percent predicted among people with cystic fibrosis ,

Impact of Gene Modifiers on Cystic Fibrosis Phenotypic Profiles: A Systematic Review

Until it's done for everyone: the role of CFTR modulator label expansion

The impact of FDA and EMA regulatory decision-making process on the access to CFTR modulators for the treatment of cystic fibrosis

S2599 A Rare Cystic Fibrosis Gene Mutation Associated With GI Manifestations in the Absence of Pulmonary Disease

Multisite Verification of a Targeted CFTR Polymerase Chain Reaction/Capillary Electrophoresis Assay That Evaluates Pathogenic Variants Across Diverse Ethnic and Ancestral Groups

Systematic Estimation of Cystic Fibrosis Prevalence in Chinese and Genetic Spectrum Comparison to Caucasians

Exploring perceptions of and decision‐making about CFTR modulators

The future of cystic fibrosis: A global perspective

An Update on CFTR Modulators as New Therapies for Cystic Fibrosis